There were 15 leading-edge genes within the NAFLD pathway, including NDUFA6, IRS1, NDUFAB1, IL6R, SREBF1, ADIPOR2, PRKAA2, NDUFA3, NR1H3, NDUFS5, UQCR11, PIK3R3, RELA, COX4I2, and NDUFA4. The five pathways identified for LMA explained phenotypic variation of 0.05, 0.07, 0.10, 0.09, and 0.11 for NAFLD, cytokine-cytokine receptor interactions, the synaptic vesicle cycle, other glycan degradation, and carbohydrate digestion and absorption, respectively. The gene discussed is PRKAA2; the disease is metabolic dysfunction-associated steatotic liver disease.